



## Genetic Factors Contributing to Disabilities

**Tyler Reimschisel, MD**  
Assistant Professor of Pediatrics and Neurology  
Associate Director, Vanderbilt LEND  
Director, Division of Developmental Medicine  
and the Center for Child Development

October 17, 2012



---

---

---


---

---

---

---

---



**“It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material...”**

**“We have also been stimulated by a knowledge of ... the unpublished experimental results and ideas of Dr. M.H.F. Wilkins, Dr R.E. Franklin and their coworkers at King’s College, London.”**

---

---

---

---



---

---

---

---

## Human Genome Published February, 2001



---

---

---

---


---

---

---

---





---

---

---


---

---

---

---

---



---

---

---


---

---

---

---

---



---

---

---

---

---

---

---

---



### Mutations and Alleles

- Mutation
  - Any change in DNA sequence
  - Not necessarily pathologic
- Allele
  - Specific DNA sequence in a gene in an individual
  - Allele 1: A at position 14
  - Allele 2: C at position 14
- Polymorphism
  - Allele present in  $\geq 1\%$
- Rare Variant
  - Allele present in  $<1\%$

---

---

---

---

---

---

---

---

### Genotype and Phenotype

- Genotype
  - Specific alleles in an individual
- Phenotype
  - Traits or characteristics of an individual
  - Product of genotype and environment
- Genotype – phenotype correlation

---

---

---

---

---

---

---

---

|  |   |
|--|---|
| <p><b><u>EXPRESSIVITY</u></b></p> <p>The extent to which a genetic defect is expressed. The trait may vary from mild to severe, but never completely unexpressed in those with the genotype.</p> | <p><b><u>PENETRANCE</u></b></p> <p>Fraction of individuals with a genotype known to cause disease who have any signs/symptoms of the disease.</p> |
|--|---|

---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---


---

---

---

---

---




---

---

---

---

---

---

---

---

### Webinar Outline

- Clinically-relevant genetic terms
- Clinical genetics evaluation for DD
- Genetic testing
  - Indications, benefits, and limitations
  - Types of genetic tests
- Genetic counseling

---

---

---

---

---

---

---

---

### Selected Indications for Referral to Genetics

- Determine genetic etiology to developmental concern (autism, ID, malformation, GDD)
- Previous child with neurodevelopmental disability or congenital malformations
- Family history of hereditary condition, including CA
- History of pregnancy loss or infertility
- Abnormal newborn screen for inborn metabolic disease
- Abnormal prenatal testing (US, maternal screen)
- Possible teratogenic effect

---

---

---

---

---

---

---

---

### Clinical Genetics Approach

- Use medical history, family history, physical examination, and prior laboratory results to determine appropriate diagnostic evaluation.
- Screen for potential comorbidities (such as hypothyroidism in DS) or malformations
- Discuss goals of care with family to determine if genetic testing is desired.
- Confirm that patient is receiving appropriate medical interventions.

---

---

---

---

---

---

---

---

### Webinar Outline

- Clinically-relevant genetic terms
- Clinical genetics evaluation for DD
- Genetic testing
  - Benefits and limitations
  - Types of genetic tests
- Genetic counseling

---

---

---

---

---

---

---

### Selected Benefits of Genetic Testing

- Treatment and management
- Prognosis (range of outcomes)
- Recurrence risk and family planning
- Potential enrollment in research study
- Potential participation in specific support group
- Empowerment

---

---

---

---

---

---

---

### Limitations of Genetic Testing

- Normal results do NOT rule out possibility of genetic etiology
- Making diagnosis of a genetic cause for DD does not *typically* guide the use of specific medication or interventions (eg. therapy)
- Financial, emotional & time costs

---

---

---

---

---

---

---

### High-Resolution Karyotype

- Microscopic evaluation of chromosomes
- Resolution: 4-5 Mb
- Identifies trisomies, translocations, inversions, large deletions or duplications
- Example conditions
  - Trisomy 21
  - Turner syndrome
  - Partial monosomies
  - Partial trisomies

---

---

---

---

---

---

---

---

### Fluorescence *In-Situ* Hybridization (FISH)

- Probe for specific area of single chromosome (locus)
- Resolution: 40,000 – 250,00 bp
- Detects deletion or duplication at locus
- Clinical conditions:
  - Velo-cardio-facial syndrome (22q11 deletion)
  - Williams syndrome (7q11.23 deletion)
  - Smith-Magenis syndrome (17p11.2)

---

---

---

---

---

---

---

---


### FISH for 22q11 Deletion

**Red signal:** Identifies chromosome 22

**Green signal:** Identifies 22q11 region

2 red signals to identify both chromosome 22s

Only 1 green signal; therefore, deletion at 22q11



---

---

---

---

---


---

---

---

### Chromosomal Microarray Analysis

- Detects submicroscopic deletions & duplications
- Example array
  - 400,000 oligonucleotides
  - Known syndrome regions
  - Subtelomere regions
  - Dispersed throughout genome
  - ≥4800 genes with exon by exon coverage
  - Complete mtDNA
- Diagnostic yield is about 8-12% for ASD and ID



<http://www.bcm.edu/cma/assets/CHIPMAPV6.pdf>

---

---

---

---

---

---

---

---

### New Genetic Syndrome

- 9 year old boy
- ID with autistic features
- Dysmorphic facial features
- Affected mother and brother
- CMA: MeCP2 duplication
- New syndrome identified in 2005 based on CMA

Del Gaudio et al. *Genet Med* 2006;8:784

---

---

---

---

---

---

---

---

### DNA Molecular Testing (Sanger Sequencing)

- Determine specific nucleotides in a particular gene or panel of genes
- Example: sequencing MeCP2 for Rett syndrome
- “Whole gene” sequencing vs. common mutations
- Possible results of testing include normal (including benign variant), abnormal and *variant of unknown significance*
- Variants of unknown significance frequently require testing of parents or other family members

---

---

---

---

---

---

---

---

## Next-Generation Sequencing (NGS)

- NGS provides opportunity to sequence the entire exome or genome
- Millions of short fragments of DNA sequenced simultaneously (massively parallel sequencing)
- Advances in IT support essential to analyze enormous volume of data (gigabytes)
- Whole exome sequencing (WES) available on a clinical basis
- Cost, time, and counseling needs are current limitations for NGS

---

---

---

---

---

---

---

---

## Biochemical Testing

- Metabolite testing (newborn screen, amino and organic acids, acylcarnitine profile)
- Large number of tests with relative low yield for most cases of developmental disability
- Pattern of abnormalities important
- Abnormal results rarely pathognomonic (diagnostic of a specific disease)
- Follow up or confirmatory analysis typically required (enzyme testing, DNA sequencing)
- (Used to follow many Pts with metabolic d/o)

---

---

---

---

---

---

---

---

## Genetic Testing

| Name   | Test   | Abnormalities Detected   |
|--|--|--|
| Karyotype  | Microscopic evaluation of all chromosomes<br>Resolution: 4-5 Mb  | Trisomies, large rearrangements, and inversions                      |
| Fluorescence <i>in situ</i> hybridization (FISH) | Single chromosome locus<br>Resolution: Submicroscopic changes (40,000 – 250,000 bp)  | Continuous gene deletions/duplications (copy number variants)        |
| Chromosomal microarray analysis (CMA)            | ≥400K oligonucleotides or millions of single nucleotide polymorphisms (SNP) ( <u>depends on version</u> )<br>Resolution: 30 Kb | Oligonucleotide or SNP duplications/deletions (copy number variants) |
| Molecular testing (Sanger sequencing)            | Sequencing of exons and exon/intron borders of specific gene(s)  | Point mutations, frameshifts, small deletions, insertions, etc.      |
| Biochemical testing                              | Metabolites associated with inborn metabolic disease, including newborn screening  | Amino acids, organic acids, acylcarnitine profile, etc.              |

---

---

---

---

---

---

---

---

### Webinar Outline

- Clinically-relevant genetic terms
- Clinical genetics evaluation for DD
- Genetic testing
  - Benefits and limitations
  - Types of genetic tests
- Genetic counseling

---

---

---

---

---

---

---

---

### Pre-test Genetic Counseling

- *Premise is that genetic testing is fundamentally different than other types of laboratory tests.*
- Provide risk assessment based on medical and family history (distinguish “genetic” from “hereditary”)
- Discuss patient’s and/or family’s priorities, values, beliefs, and goals
- Discuss benefits and limitations of performing genetic testing and not performing genetic testing
- Describe genetic testing options
- Describe logistics of genetic testing
- Discuss potential results of testing
- Provide psychosocial support with referrals, if indicated

---

---

---

---

---

---

---

---

### Post-test Genetic Counseling

- Disclose genetic test results and prognosis
- Review expressivity and penetrance of condition
- Discuss treatment options for patient
- Review recurrence risk and reproduction options based on results of testing
- Provide psychosocial support with referrals, if indicated.
- Document information in counseling letter

---

---

---

---

---

---

---

---

## Clinical Genetics References

- Gene Tests ([www.geneclinics.org](http://www.geneclinics.org))
- Online Mendelian Inheritance in Man (OMIM) website
- Gorlin, Cohen, and Hennekam. Syndromes of the Head and Neck. Oxford, 2001.
- Cassidy SB and Allanson JE. *Management of Genetic Syndromes, Second Edition*. Wiley, 2005.

---

---

---

---

---

---

---

---

The screenshot shows the AUCD 2012 website for a pre-conference workshop. The header includes the AUCD logo and the slogan "Innovating Today Shaping Tomorrow" with the date "December 2-5, 2012 Washington, DC". The main content area is titled "AUCD - Pre-Conference Workshop 7: Essential Clinical Genetics for LEND and UCEDD Programs". It lists the date as "Sunday, December 2, 2012 12:30 PM - 3:00 PM" and the location as "Columbia 10". A list of featured presenters includes Tyler Reimschisel, Robert W. Martin, Karen Edwards, John Moschler, and Jaemin Bodurha. A session description follows, explaining that the workshop will provide knowledge and skills for healthcare professionals to integrate genetics into the care of individuals with neurodevelopmental disabilities. A sidebar on the left contains navigation links such as Home, Conference Invitation & Overview, Presentation Details, and Registration. A URL is provided at the bottom: [http://www.aucd.org/conference/detail/session\\_event\\_id=388&showday=1](http://www.aucd.org/conference/detail/session_event_id=388&showday=1), accessed October 16, 2012.

---

---

---

---

---

---

---

---

## Questions?

[tyler.reimschisel@vanderbilt.edu](mailto:tyler.reimschisel@vanderbilt.edu)

---

---

---

---

---

---

---

---